1. Introduction {#s0005}
===============

Attention deficit hyperactivity disorder (ADHD) is characterized by a behavioral phenotype of inattention, hyperactivity and impulsivity, affecting between 3 and 7% of school-aged children in the U.S. ([@bb0110; @bb0355]). The symptoms of ADHD can usually be identified during their early elementary school years ([@bb0115]). Diagnosis of ADHD typically refers to the degree of the symptoms listed in the diagnostic criteria from the DSM-IV ([@bb9000]), which requires rating by the parents or teachers of the children, and thus often entails subjective evaluation. Thus, more objective approaches, preferably based on biomarkers, are a compelling need ([@bb0520; @bb0535]).

One promising approach is noninvasive functional neuroimaging in combination with neuropsychological tests. A wealth of functional neuroimaging research has started to explore the neural substrates of ADHD. The majority of such research performed thus far has used functional magnetic resonance imaging (fMRI), and many studies have reported less prefrontal activation with ADHD during performance of various cognitive tasks (e.g., [@bb0060; @bb0370; @bb0385; @bb0445]). However, most of the fMRI studies are on adult ADHD patients with only limited implications for children. Among approximately one hundred ADHD-related fMRI studies, twenty-six included patients at the age of eight, eleven at the age of seven ([@bb0010; @bb0045; @bb0060; @bb0070; @bb0120; @bb0155; @bb0350; @bb0440; @bb0450; @bb0480; @bb0505]) and only two at the age of six ([@bb0135; @bb0480]).

The scarcity of child ADHD studies is due to technical obstacles. Severely hyperactive children could not be included in the studies because motion artifacts would have prevented successful fMRI measurement ([@bb0500]). This leads to a high elimination rate due to excessive motion artifacts: One study enrolling a relatively young childhood sample (6 years and older) rejected 50% of ADHD subjects and 30% of normal control subjects ([@bb0135]). This further leads to a skewed distribution of the sample: Since motion problems are generally more severe for patients with hyperactivity, the resulting subject pool might be enriched with mildly and predominantly inattentive type patients ([@bb0150]). Moreover, ADHD children may be withdrawn for various reasons related to their symptoms including refusal to enter the MRI scanner, refusal to begin or finish a run after entering the MRI scanner, inattention such as forgetting task rules, and falling asleep ([@bb0530]).

Alternatively, functional near-infrared spectroscopy (fNIRS) is relatively immune to these problems, and has been successfully adopted in tasks involving body movement ([@bb0195; @bb0200; @bb0285; @bb0345; @bb0210; @bb0280; @bb0300; @bb0335; @bb0420; @bb0465]). Moreover, fNIRS offers other advantages including its compact size (useful in confined experimental settings), affordable price, unrestrictiveness and accessibility, serving as a suitable choice for clinically assessing ADHD children. A growing body of fNIRS studies has started to investigate the cortical hemodynamics of ADHD patients ([@bb0140; @bb0215; @bb0320; @bb0395; @bb0400; @bb0515]). Most typically, a recent study focusing on Stroop interference revealed that the right prefrontal cortex oxy-Hb increase due to Stroop interference was reduced in ADHD children, suggesting a dysfunction of the area ([@bb0220]).

The advent of fNIRS raised the possibility of introducing neuroimaging diagnosis in younger ADHD children, and this might further lead to its application in early clinical treatment. The most common treatment for ADHD children is the administration of methylphenidate (MPH), a psychostimulant drug that has been shown to be effective in improving attention and behavior as well as cognition and social function ([@bb0455]). The behavioral and cognitive characteristics of ADHD are considered to be partly due to dopamine and noradrenaline dysfunction ([@bb0525]). MPH is considered to inhibit reuptake of catecholamines, including dopamine, by blocking their transporters and to act as a dopamine agonist in the basal ganglia and cerebral cortices ([@bb0015]). A recent longitudinal study reported that the use of MPH to treat children and adolescents with ADHD may be conducive to enhancing educational outcomes by reducing the likelihood of disruptive behavior ([@bb0050]). To confer long-term positive effects of treatment and thereby increase the quality of life of ADHD children, early identification of ADHD and appropriate treatment are important. This led us to postulate that fNIRS would be effective in monitoring the effect of MPH in ADHD children, especially for younger children who are difficult to assess in an fMRI environment.

Response inhibition as measured by go/no-go tasks has emerged as one of the principal paradigms for studying ADHD ([@bb0025]). Using this task, it has been clearly demonstrated that children ([@bb0035; @bb0095; @bb0135; @bb0215; @bb0270; @bb0295; @bb0435; @bb0445; @bb0450; @bb0500]), adolescents ([@bb0405; @bb0470]) and adults ([@bb0100; @bb0230; @bb0315; @bb0410; @bb0510]) with ADHD have response inhibition deficits. An extensive review of functional neuroimaging in healthy adults indicates that widespread regions of the frontal cortex, especially the right inferior frontal gyrus (IFG), are associated with response inhibition ([@bb0025]). Structural neuroimaging in ADHD has fairly consistently indicated gray matter density reductions in the striatum and right IFG ([@bb0125]). A former fMRI study on ADHD children with an MPH history reported that MPH increased the activation of the frontal cortices and striatum in go/no-go tasks ([@bb0500]). The specificity of the implicated brain regions in healthy subjects, as well as functional and structural changes to those regions in ADHD patients, suggests that response inhibition is a good neuro-functional biomarker candidate for ADHD ([@bb0025]).

Thus, using the decrease of IFG activation during a response inhibition task as a potential neuro-functional biomarker for ADHD, we aimed to establish a robust procedure for detecting its recovery with MPH administration. Our initial effort ([@bb0295]) was to test whether fNIRS-based diagnosis could be introduced in actual clinical situations. We demonstrated that fNIRS could monitor the cortical hemodynamics of ADHD children (7 to 14 years old) performing a go/no-go task before and 1.5 h after MPH administration, allowing the observation of the acute effect of MPH as a significant increase in the oxy-Hb signal in the right lateral prefrontal cortex. As the monitoring takes only a few minutes, we further showed that the entire process can be implemented within a single-day hospital visit.

However, since that study was optimized for assessing the feasibility of introducing fNIRS as an actual clinical tool that allows the pre- and post-medication comparison to be performed in a single-day hospital visit, a neuro-pharmacological examination of the effects of MPH on ADHD children has yet to be performed. Thus, in the current study, enrolling sixteen ADHD children and age/sex-matched healthy control children, we examined the pharmacological effects of MPH on the cortical hemodynamics of ADHD during a go/no-go task. Subjects received either MPH or a placebo in a randomized, double-blind, placebo-controlled, crossover design. We hypothesized that MPH would modulate hemodynamic responses in the right prefrontal cortex during a go/no-go task while a placebo would not, and assessed this hypothesis using fNIRS. Moreover, we desire to validate the feasibility of introducing fNIRS-based diagnosis of the effects of MPH administration to ADHD children of 6 years old, the earliest age at which the FDA recommends starting MPH administration.

2. Material and methods {#s0010}
=======================

2.1. Subjects {#s0015}
-------------

Sixteen clinically referred, right-handed Japanese children with a mean age of 8.8 (SD 2.2, range 6--13 years) who met the DSM-IV criteria for ADHD participated in the study ([Table 1](#t0005){ref-type="table"}). The subject group differed from the previous study ([@bb0295]). The Wechsler Intelligence Scale of Children---Third Edition (WISC-III) full IQ scores of subjects were all over 70 (mean 90.3, SD 10.0, range 74--110). Sixteen right-handed control subjects were matched with the ADHD subjects according to age (mean 8.9, SD 2.4, range 6--13 years) and gender (10 boys and 6 girls). IQs of controls (mean 111.8, SD 8.7, range 99--135) were significantly (*t* = 6.40, *p* \< 0.0001) higher than those of ADHD subjects. Written consent was obtained from the parents of all subjects. The study was approved by the Ethics Committees of Jichi Medical University Hospital, and the International University of Health and Welfare. The study was in accordance with the latest version of the Declaration of Helsinki. This study was registered to UMIN-CTR Clinical Trial (UMIN000006277) as "Neurophysiological analysis in developmental disorders: an exploratory neuroimaging study using functional near-infrared spectroscopy (fNIRS)".

2.2. Experimental design {#s0020}
------------------------

The effects of MPH were examined in a randomized, double-blind, placebo-controlled, crossover study while the subjects performed a go/no-go task. Experimental procedure is summarized in [Fig. 1](#f0005){ref-type="fig"}. ADHD subjects were examined twice (the times of day for both measurements were scheduled to be as close as possible), at least 4 days apart, but within 30 days. Control subjects only underwent a pre-administration session.

On each examination day, ADHD subjects underwent two sessions, one before drug (MPH or placebo) administration, and the other at 1.5 h after the drug administration. Each session consisted of 6 block sets, each containing alternating go (baseline) and go/no-go (target) blocks. Each block lasted 24 s and was preceded by instructions displayed for 3 s, giving an overall block-set time of 54 s and a total session time of 5.5 min. In the go block, subjects were presented a random sequence of two pictures and asked to press a button for both pictures. In the go/no-go block, subjects were presented with a no-go picture 50% of the time, thus being required to respond to half the trials (go trials) and inhibit their response to the other half (no-go trials). A go/no-go ratio of 50% was selected as it has been most often used in former neuroimaging studies ([@bb0105; @bb0200; @bb0260; @bb0290; @bb0500]). Pictures were presented with 1 Hz frequency during go and go/no-go blocks. At the beginning of each block, instructions (e.g., "press for tiger or elephant" for go conditions and "do not press for giraffe" for go/no-go conditions) were displayed for 3 s to inform the subject about the new block. Each subject performed a practice block before any measurements to ensure their understanding of the instructions.

After ADHD subjects performed the first session, either MPH (OROS-methylphenidate or Concerta) or a placebo was administered orally. Specific acute doses were the same as their daily dose as described in [Table 1](#t0005){ref-type="table"}.

2.3. fNIRS measurements {#s0025}
-----------------------

We used the multichannel fNIRS system ETG-4000 (Hitachi Medical Corporation, Kashiwa, Japan), using two wavelengths of near-infrared light (695 and 830 nm). We analyzed the optical data based on the modified Beer--Lambert Law ([@bb0075]) as previously described ([@bb0275]).

We set the fNIRS probes to cover the lateral prefrontal cortices in reference to previous studies ([@bb0185; @bb0195; @bb0200; @bb0260; @bb0295; @bb0380]), resulting in 22 channels (CH) per hemisphere. The specific setting was as previously described ([@bb0295]). After the fNIRS measurement, positional data of illuminators and detectors were obtained for both the ADHD and control subjects using a 3D-digitizer (Fastscan, Polhemus), and subjected to probabilistic registration of fNIRS channel positions to MNI space ([@bb0225; @bb0330; @bb0340; @bb0430; @bb0495; @bb0490]) with reference to macroanatomical brain atlases ([@bb0360; @bb0415]).

Oxy-Hb signals were used for further analysis due to its higher signal amplitude than that of deoxy-Hb ([@bb0460]). Individual timeline data for the oxy-Hb signals of each channel were preprocessed with a first-degree polynomial fitting and high-pass filter using cut-off frequencies of 0.01 Hz to remove baseline drift, and a 0.8 Hz low-pass filter to remove heartbeat pulsations. After removal of blocks with marked motion-related artifacts, timeline data of the remaining blocks (where more than 4 blocks remained) were used. From the preprocessed time series data, we obtained channel-wise and subject-wise contrasts by calculating the inter-block means of difference between the target (4--24 s after go/no-go block onset) and baseline (14--24 s after go block onset) periods.

2.4. Statistical analyses {#s0030}
-------------------------

We performed statistical analyses in a channel-wise manner on oxy-Hb signals. Specifically, for control subjects who were examined only once, the target vs. baseline contrast of the session was generated. For ADHD subjects, the following contrasts were generated: (1) first-day, pre-medication contrast: target vs. baseline contrast for the pre-medication condition (either placebo or MPH administration) for the first day exclusively; (2) pre-medication contrasts: target vs. baseline contrast for the pre-placebo and pre-MPH conditions (for either first or second day measurements); (3) post-medication contrasts (specifically, post-placebo and post-MPH contrasts): target vs. baseline contrast for the post-placebo and post-MPH conditions; (4) intra-medication contrasts: difference between post- and pre-medication contrast for each medication (i.e., intra-placebo and intra-MPH contrasts); and (5) inter-medication contrast: difference between intra-MPH and intra-placebo contrasts. Note that (2) and (4) were generated temporally for calculating (5).

To screen the channels involved in go/no-go tasks in normal control subjects, target vs. baseline contrasts were subjected to one-sample *t*-tests against zero (two-tails). Statistical threshold was set at 0.05 with Bonferroni method for family-wise error correction. For thus-screened channels, comparisons between control and ADHD were performed for the following three ADHD contrasts: (1) first-day, pre-medication, (2) post-placebo, and (3) post-MPH. They were subjected to independent two-sample *t*-tests (two-tails) with a statistical threshold of *p* \< 0.05. For examining medication effects on ADHD subjects, comparison between intra-MPH and intra-placebo (i.e., inter-medication contrast) was subjected to one-sample *t*-tests against zero (two-tails) with a statistical threshold of *p* \< 0.05.

2.5. Behavioral data analysis {#s0035}
-----------------------------

The reaction time (RT) of go trials, and accuracy (ACC) for go and no-go trials were computed for each go/no-go block. ACCs and RTs were averaged across go/no-go blocks, and subjected to statistical analyses as described in the previous section. Statistical threshold was set at 0.05 with Bonferroni method for multiple-comparison error correction (i.e., significant *p* was \< 0.05/3).

3. Results {#s0040}
==========

3.1. Behavioral performance {#s0045}
---------------------------

The average ACC for go and no-go trials and RT for correct go trials in the go/no-go block for control and ADHD subjects are summarized in [Table 2](#t0010){ref-type="table"}. In ADHD subjects, the first-day data before administration of either a placebo or MPH was used as a representation of pre-medication contrast. Second-day data was excluded for this contrast.

First-day pre-medication, post-placebo, and post-MPH values of ADHD subjects were compared with values for control subjects ([Table 2](#t0010){ref-type="table"}). Significant differences in ACC for no-go trials were found between control subjects and first-day pre-medication ADHD subjects and between control subjects and post-placebo ADHD subjects.

For analysis within each ADHD subject, the inter medication contrast comparing the effect of MPH against the placebo revealed no significant differences in behavioral parameters ([Table 3](#t0015){ref-type="table"}).

3.2. fNIRS analyses {#s0050}
-------------------

We screened for any fNIRS channels involved in the go/no-go task for the control subjects. Significant oxyHb increase was found in the right CH 10 (mean 0.075, SD 0.074, *p* \< 0.05, Bonferroni-corrected, Cohen\'s d = 1.009). This channel was located in the border region between the right MFG and IFG (MNI coordinates x,y,z (SD): 46,43,30 (14), MFG 78%, IFG 22% with reference to macroanatomical brain atlases ([@bb0360; @bb0415])). Thus, we set the right CH 10 as a region-of-interest (ROI) for the rest of the study. For reference, cortical activation patterns with all the channels are presented for control and ADHD subjects as supplementary material.

Comparison between oxy-Hb signals of the control and first-day pre-medicated ADHD subjects revealed significantly higher oxy-Hb signal in the right CH 10 in the control subjects (independent two-sample *t*-test, *p* \< 0.05, Cohen\'s *d* = 0.839, [Table 2](#t0010){ref-type="table"}). This indicates that the control subjects exhibited higher right prefrontal activation during go/no-go tasks than did the pre-medicated ADHD children.

Effects of medications were examined between control and post-placebo ADHD subjects, and between control and post-MPH ADHD subjects (independent two-sample *t*-test, thresholded at *p* \< 0.05). Oxy-Hb signal in control was significantly higher than in post-placebo ADHD subjects, whereas no significant difference was found for those in control and post-MPH ADHD subjects ([Table 2](#t0010){ref-type="table"}). This suggests that the impaired right prefrontal activation in pre-medicated ADHD subjects was normalized by the MPH administration.

Finally, we tested whether there was an MPH-induced, but not placebo-induced, right prefrontal activation in ADHD children. In the inter-medication contrast, the right CH 10 was found to be significant with a large effect size (one-sample *t*-test, *p* \< 0.05, Cohen\'s *d* = 0.952, [Table 3](#t0015){ref-type="table"}). This result indicates that the oxy-Hb signal increase during go/no-go tasks was induced by MPH but not by the placebo.

3.3. Oxy-Hb timeline data {#s0055}
-------------------------

[Fig. 2](#f0010){ref-type="fig"} illustrates the grand average waveforms of all 16 control subjects and 16 ADHD subjects. For ADHD, oxy-Hb and deoxy-Hb signals are presented for pre-/post-placebo and pre-/post-MPH conditions on CH 10 of the right hemisphere. We observed more stable task-related oxy-Hb signals than deoxy-Hb signals, suggesting the robustness of oxy-Hb signals for our experimental conditions. An oxy-Hb increase in the right CH 10 was clearly observed for control and post-MPH administration of ADHD in the grand average waveform. Waveforms for individual subjects (subject 5: 6-year-old ADHD girl, and subject 1: 7-year-old ADHD boy) are also illustrated. Although the individual data resulted in somewhat noisy waveforms, the oxy-Hb activation in the post-MPH session is clearly presented even in the data of the 6-year-old ADHD subject.

3.4. Examination on the effects of IQ {#s0060}
-------------------------------------

Since we did not match the IQ of the ADHD and normal healthy control subjects, we performed additional analyses to find the possible effects of IQ. We examined the correlation between IQ and activation in the right CH 10 for ADHD children (ADHD 1st day pre-medication contrast) and normal healthy control children, respectively. In ADHD children, Pearson\'s correlation coefficient was 0.184 (*p* = 0.494), while that in control children was 0.010 (*p* = 0.969): Neither analysis yielded any significant correlation with a meaningful effect size. In addition, we examined whether the two correlation coefficients were different, but did not find any significant difference (Fischer\'s *z* = 0.45, *p* \> 0.05). Thus we concluded there was no correlation between IQ and the activation in the right CH 10 in either group.

4. Discussion {#s0065}
=============

The current study exploring fNIRS-based diagnosis of the effects of MPH administered to ADHD children revealed that the right IFG/MFG activation could serve as an objective neuro-functional biomarker for fNIRS measurement. First, relative to control subjects, unmedicated ADHD children exhibited reduced brain activation in the right IFG/MFG during go/no-go task blocks. Second, the reduced right IFG/MFG activation was acutely normalized after MPH administration, but not after placebo administration. Third, the MPH-induced right IFG/MFG activation was significantly larger than the placebo-induced activation.

4.1. Behavioral performance for go/no-go task {#s0070}
---------------------------------------------

The current fNIRS analyses adopted the contrast of go/no-go against go tasks. In addition to response inhibition, this contrast is thought to commeasure additional cognitive functions, including decision making, response competition/response selection, conflict monitoring, and increased attentional demand ([@bb0260; @bb0290; @bb0375; @bb0380]). Thus, the fNIRS results are expected to reflect a rather wide spectrum of cognitive functions associated with ADHD. On the other hand, neuropsychological tests are expected to examine specific cognitive aspects of ADHD symptoms. Go errors (omission errors) are typically considered indicators of inattention to the task, while no-go errors (commission errors) and RT to go responses are considered indicators of impulsivity ([@bb0030; @bb0325]). Numerous studies have demonstrated that MPH improves no-go indices in child and adult ADHD patients ([@bb0020; @bb0025; @bb0040; @bb0475]). However, MPH also affects the speed of go responses, go response variability, and discrimination errors in go trials ([@bb0025; @bb0040; @bb0475]). Moreover, Rubia et al. suggested that the beneficial MPH effects were more pronounced for inattention problems (reflected by omission errors) than impulsivity (reflected by commission errors) ([@bb0365]).

In the current study, the comparison between controls and unmedicated ADHD patients showed a significantly higher commission error rate for ADHD subjects. This result was mostly in line with former studies. We detected no significant behavioral performance differences in the MPH-medicated ADHD children contrasted against control subjects, suggesting an MPH effect for no-go performance. However, the inter-condition contrast representing MPH effects against placebo failed to yield any significant behavioral performance change. Although behavioral parameters may often well reflect specific cognitive aspects of ADHD symptoms or MPH effects on them, the current study could not confirm a normalization effect of MPH (but not placebo) on behavioral parameters.

4.2. Right IFG/MFG activation as a robust neuro-functional biomarker {#s0075}
--------------------------------------------------------------------

On the other hand, fNIRS may provide more robust measures of MPH effects. Previous neuroimaging studies have elucidated the neural correlates of go/no-go tasks ([@bb0425]), including the bilateral IFG, MFG and SFG (superior frontal gyrus), supplementary motor area, anterior cingulate gyrus, inferior parietal and temporal lobes, caudate nucleus, and cerebellum ([@bb0380]). The IFG may be specifically related to motor response inhibition, while the MFG/SFG, medial prefrontal, and parietal cortices possibly mediate more general meta-motor executive control functions such as motor attention, conflict monitoring, and response selection, necessary for inhibition task performance ([@bb0375]).

Among these regions, our fNIRS measurements covered the right and left IFG (BA 44/45), MFG (BA 46/9), and SMG (supramarginal gyrus, BA40), and we found activation in the right MFG and IFG (BA9, 46, 45) during the go/no-go task period in the control subjects, but not in the first-day, pre-medicated ADHD subjects. These results suggest that the right prefrontal function associated with the go/no-go task performance was impaired in ADHD children. The administration of a placebo did not result in right prefrontal activation, while that of MPH led the ADHD children to exhibit a degree of right prefrontal activation comparable to that of the normal control subjects. Moreover, the right prefrontal activation due to MPH administration was significantly higher than that due to placebo administration. These results led us to conclude that MPH had significant effects in normalizing right frontal dysfunctions in ADHD children.

The right prefrontal dysfunction and MPH-elicited recovery observed by fNIRS are consistent with former studies using other neuroimaging modalities. A recent ALE meta-analysis of go/no-go tasks ([@bb0065]) reported a mainly right-lateralized network associated with response inhibition, including the right MFG and IFG (BA46/44), the right SMG (BA40), and the superior medial frontal gyrus (BA6) ([@bb0425]). These regions have been implicated in the processes of stimulus recognition, maintenance and manipulation of stimulus--response associations and response selection, including selecting not to respond ([@bb0190; @bb0255; @bb0260; @bb0305; @bb0375]), all of which are critical to the performance of go/no-go tasks ([@bb0425]). fMRI studies of the go/no-go task have consistently recruited frontal cortices; however, localization and the extent of frontal activation vary across these studies, with activation most often localized to the right IFG (BA 45/47) ([@bb0130; @bb0185; @bb0240; @bb0375]), followed by the right MFG/SFG (BA9/46) ([@bb0185; @bb0180; @bb0175; @bb0170; @bb0205; @bb0310]). An fNIRS study also added further evidence to the involvement of the right lateral prefrontal cortex (more exactly, F4) during go/no-go tasks ([@bb0055]). Another recent fNIRS study reported reduced prefrontal activation in ADHD children compared to normal controls during a go/no-go condition (albeit no laterality was reported) ([@bb0215]). Moreover, recent fMRI studies on MPH-medicated children have provided more direct evidence for cortical activation and MPH treatment. Using a continuous performance task, [@bb0365] found that MPH treatment improved under-activation in ADHD children compared to normal children by adding activation in the right IFG and MFG along with several other regions ([@bb0295]). Therefore, it would be relevant to suggest that normalized right IFG/MFG activation induced by MPH administration during go/no-go task serves as a robust neuro-functional biomarker for fNIRS assessment of MPH effect on ADHD children.

4.3. Effects of IQ {#s0080}
------------------

We did not match the IQs of ADHD and normal healthy control children. However, this did not seem to cause any serious effects on the findings of the current study, as we did not find any correlation between IQ and the activation in the right CH 10 in either group. There have been arguments over whether to match IQ or not in ADHD studies. The IQs of ADHD children are lower than those of normal healthy children ([@bb0165; @bb0245]), and an extensive epidemiological study reported that the co-occurrence of ADHD and low IQ has a genetic overlap ([@bb0085]). Therefore, it is not considered appropriate to treat IQ as a covariant of ANCOVA type of studies ([@bb0085; @bb0090]). If IQ had been used as a covariant, the differences in cortical activation in ADHD and normal healthy control children would have been over-corrected since IQ is relevant to the brain phenotype of the disorder ([@bb0085]).

Moreover, IQ measurement of ADHD children poses a problem intrinsic to ADHD symptoms: it is sometimes difficult for young ADHD children to execute IQ tests as they are not always sufficiently patient. Thus, the IQs of ADHD children might be underestimated, and not adequately reliable.

Previous reports adopting an IQ match between ADHD and normal healthy children enrolled ADHD children with relatively high IQs ([@bb0020; @bb0060; @bb0070; @bb0120; @bb0270; @bb0320; @bb0400; @bb0500; @bb0530]). Most of these studies excluded low-IQ ADHD children with criteria such as IQ \> 85 or IQ \> 90 ([@bb0020; @bb0270; @bb0500; @bb0530]). We calculated the average IQ of ADHD children in these studies and found that it was 108 ± 8 (mean ± SD). There is a possibility that low-IQ ADHD children with severe behavioral rating scores had been selectively excluded.

On the other hand, our IQ criterion was greater than 70, which is among the most lenient criterions together with two other recent studies ([@bb0215; @bb0320]). Such samples are expected to represent the ADHD population in a balanced manner as they include severe patients. While there might be other possibilities for matching ADHD IQs with those of normal healthy children with low IQs, it is difficult to match the IQs of normal healthy children to those of ADHD groups including children with low IQs, and no study has performed matching for such low scores. Moreover, even if IQ matching had been realized, such samples would not have represented general healthy children.

Although IQ matching for ADHD and control children poses several problems as mentioned above, we do not mean that it should be avoided. Rather, IQ-matching studies should be pursued with different perspectives, such as to assess the effects of IQ, and should be undertaken in the future. As de Zeeuw reported ([@bb0085]), the brains of low-IQ ADHD children might undergo different functional and anatomical development. If this is the case, subdividing the whole group to yield low-IQ groups would be of great clinical importance. For this purpose, the current system, which can measure severely ADHD children with low IQs, would serve as a valuable tool.

4.4. Limitations {#s0085}
----------------

A few limitations should be noted for adequate understanding of the current findings. First, a learning effect associated with go/no-go tasks cannot be excluded from the current experimental design: while control subjects underwent only one task session, ADHD children underwent two sessions in the same day. Thus, the effects of habituation ([@bb0160; @bb0235; @bb0265]) and procedural learning ([@bb0145]) could be present. First-day pre-medicated data (i.e., either pre-placebo or pre-MPH) was used for the ADHD group to compare the two groups (ADHD and control) under conditions not affected by these factors. However, post-medication data are by necessity from the second sessions. For separate sessions of the same task, an activation of greater magnitude has been observed for the first session for go/no-go tasks in fMRI studies ([@bb0250]). Thus, it was expected that the oxy-Hb amplitude of the second, post-medicated, sessions would be reduced. However, in the current study, MPH administration to ADHD children still led to increased oxy-Hb amplitude comparable to that of control children. This indicates that MPH exerted pharmacological effects beyond the level needed to compensate for the expected habituation and learning effects.

Second, the current study limited the analyses to the oxy-Hb parameter because we did not find any channels with significant activation with the deoxy-Hb parameter during the screening process performed on normal healthy control subjects. Thus, we concluded that deoxy-Hb was not suitable for further analysis in the current study.

Many fNIRS studies have solely reported the results of the oxy-Hb parameter, including an ADHD study by [@bb0320]. There is a tendency that oxy-Hb is more sensitive than deoxy-Hb (e.g. [@bb0140; @bb0215; @bb0515]), but the precise reason for the decreased sensitivity of deoxy-Hb has yet to be elucidated. Our previous study adopting a similar experimental paradigm also failed to detect activation with the deoxy-Hb parameter ([@bb0295]). [@bb0140] reported that deoxy-Hb behavior was different between ADHD and normal subjects: deoxy-Hb decreases were larger in ADHD subjects than in normal subjects. In addition, even when oxy-Hb increased, the deoxy-Hb parameter either increased, remained unchanged or decreased depending on tasks, regions, age and so on ([@bb0140; @bb0390]), suggesting difficulty in dealing with the deoxy-Hb parameter. Further exploration is necessary to elucidate the role and applicability of the deoxy-Hb parameter.

4.5. Clinical utility of fNIRS-based examination {#s0090}
------------------------------------------------

In the current study, we adopted a go/no-go task paradigm with alternating go and go/no-go blocks. [@bb0485] and [@bb0080] employed alternating go and go/no-go tasks, and used the go task as a baseline contrast for the go/no-go task fNIRS signal that they were interested in. Similarly, we used the go block as a baseline period, and did not adopt rest periods. This was primarily because it is extremely difficult for ADHD patients to stay still without performing any task: it may lead to unexpected movements or behaviors. Secondarily, we could save time by omitting rest blocks: a prolonged experiment time may bore ADHD subjects. Finally, experimental paradigms employing alternate go and go/no-go blocks have been commonly used in fMRI studies ([@bb0005; @bb0105; @bb0270; @bb0500]) and also in fNIRS studies ([@bb0485]). Thus, considering comparisons across modalities, the choice of experimental paradigm in the current study is appropriate.

An additional merit of the alternative task paradigm is that go blocks can serve as a motor control for go/no-go blocks. [@bb0395] performed weekday reciting task and word fluency tasks and used the weekday reciting task as a baseline to which fNIRS signal during the word fluency tasks was compared. By using a control condition with a similar motor output, movement and muscle artifacts in a task condition are expected to be cancelled. Similarly, we adopted the go task as a baseline period. During the go task period, subjects are expected to press a button twice as often as in the go/no-go task period, assuming that they perform the tasks appropriately. Due to the nature of go/no-go tasks, that go periods require increased response, we cannot fully equalize the motor loads of go and go/no-go periods. However, since motor effects are considered larger during the go period, we can expect that a go/no-go vs. go contrast would rule out motion artifacts. Accordingly, activation in a go/no-go task block is considered to reflect response inhibition and target detection, and is therefore more appropriate than a rest block as a baseline. Although fNIRS studies often use a paradigm where rest and task blocks were alternately performed ([@bb0200]), we suggest that it would be more suitable for studies using younger ADHD children to adopt experimental paradigms employing alternate go and go/no-go blocks, which have been commonly used in fMRI studies ([@bb0005]; [@bb0105; @bb0270; @bb0500]).

5. Conclusion {#s0095}
=============

In the current study exploring fNIRS-based diagnosis on the effects of MPH administration to ADHD children using a double-blind, placebo-controlled, cross-over design, we presented the following findings: 1) Relative to control subjects, unmedicated ADHD children exhibited reduced brain activation in the right IFG and MFG during go/no-go task blocks. 2) The reduced activation in the right inferior and middle frontal gyri was acutely normalized after MPH administration, but not after placebo administration. 3) Compared to the placebo-induced activation, the MPH-induced right IFG/MFG activation was significantly larger. These findings led us to conclude that the activation in the right inferior and middle frontal gyri could serve as an objective neuro-functional biomarker to indicate the effects of MPH on ADHD children. fNIRS-based examination on the effect of MPH was applicable to ADHD children as young as 6 years old. This promising technique will enable the early clinical diagnosis and treatment of ADHD children.

Appendix A. Supplementary data {#s0100}
==============================

The following is the Supplementary data to this article.Supplementary Fig. 1Cortical activation pattern of control subject (a) and post-MPH session of ADHD subjects (b). They are shown as t-maps of oxy-Hb signal, with significant t-values (one-sample *t*-test, *p* \< .05 uncorrected) being shown according to the color bar. We screened for any channels involved in the go/no-go task for the control subjects. Significant increase was found in two channels on the left hemisphere (CHs 10 and 14) and five channels on the right hemisphere (CHs 1, 5, 6, 10, and 15). Among these channels, the right CH 10 exhibited the most significant increase with a large ES (1.009), and was the only channel remaining after family-wise error correction (Bonferroni, *p* \< 0.05). Therefore, right CH 10 was determined as a channel of interest in the main analyses. In ADHD subjects, significant MPH-effects on oxy-Hb increase were found in four channels on the right hemisphere (CHs 5, 10, 18, and 22), whereas 1st-day pre-medication and post-placebo contrast revealed no significant channel (data not shown).
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![Experimental design. a. A schematic showing the flow of pre- and post-medication administration sessions for ADHD subjects. b. fNIRS measurements. Brain activity was measured while ADHD and control subjects performed the go/no-go task.](gr1){#f0005}

![The channel location and waveforms of oxy-Hb (red line) and deoxy-Hb (blue line) signals for right CH 10. The green area indicates the go/no-go task period. Significant (one-sample *t*-test, *p* \< .05) conditions are indicated by asterisks. a. On-brain channel locations (right hemisphere) are statistically estimated for the group of subjects (including both ADHD and control) and exhibited in MNI space. CH 10 is indicated in red. b. Grand averages for control subjects. Standard deviations among the 16 subjects are exhibited as pale red (oxy-Hb) and blue dotted (deoxy-Hb) areas. Each time line is adjusted to the average value for a baseline period of zero. Oxy-Hb and deoxy-Hb signals are shown in units of mM·mm. c. Grand averages for ADHD subjects for pre-/post- and placebo/MPH conditions are illustrated. d. Graphs for ADHD individuals for pre-/post- and placebo/MPH conditions. Subject 1 is a 7-year-old boy and subject 5 is a 6-year-old girl (corresponding to [Table 1](#t0005){ref-type="table"}).](gr2){#f0010}

###### 

Demographic and clinical profiles for ADHD subjects.

  --------------------------------------------------------------------------------------------------------------------------------------------
  ID     Age\      Sex   ADHD subtype   Complication   WISC-III full IQ   MPH dose\   Duration of MPH exposure\   Other medications
         (years)                                                          (mg)        (years)                     
  ------ --------- ----- -------------- -------------- ------------------ ----------- --------------------------- ----------------------------
  1      7         M     Inattentive    None           110                18          1.0                         None

  2      8         M     Combined       None           95                 27          1.0                         None

  3      12        M     Combined       PDD            96                 27          1.8                         None

  4      11        M     Combined       None           82                 27          3.4                         None

  5      6         F     Hyperactive    None           98                 18          0.6                         None

  6      7         M     Combined       PDD            79                 18          Naïve                       None

  7      13        M     Combined       None           82                 45          2.1                         Carbamazepine, risperidone

  8      8         F     Combined       PDD            85                 18          Naïve                       None

  9      8         F     Combined       Epilepsy       85                 18          Naïve                       Valproic acid

  10     8         M     Combined       PDD            101                18          2.0                         None

  11     8         M     Combined       None           90                 27          2.2                         None

  12     7         M     Combined       None           95                 18          Naïve                       None

  13     6         F     Inattentive    None           74                 18          Naïve                       None

  14     10        M     Combined       None           105                18          Naïve                       None

  15     9         M     Combined       None           85                 18          Naïve                       None

  16     12        M     Combined       None           90                 18          0.1                         None

  Mean   8.8                                           90.8                                                       

  SD     2.2                                           9.9                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: SD, standard deviation; PDD: pervasive developmental disorders.

###### 

Go/no-go task performance and functional data for control and ADHD subjects.

                                  Control   ADHD                                                                                                      
  ------------------------------- --------- ------- ------- ------- ------- ----------- ------- ------- ------- ----------- ------- ------- --------- -----------
  ACC for go trials (%)           96.5      5.48    86.2    21.9    1.829   0.085^ns^   85.3    20.2    2.14    0.047^ns^   92.3    12.0    1.266     0.219^ns^
  ACC for no-go trials (%)        95.2      4.52    86.6    11.9    2.688   0.014^⁎^    86.5    8.46    3.634   0.001^⁎⁎^   89.5    8.51    2.347     0.028^ns^
  RT for correct go trials (ms)   421.4     57.5    385.5   96.8    1.275   0.214^ns^   377.0   83.6    1.753   0.091^ns^   404.9   47.9    0.881     0.386^ns^
  Oxy-Hb right CH10 (mM·mm)       0.075     0.074   0.008   0.084   2.374   0.024^⁎^    0.001   0.087   2.586   0.015^⁎^    0.077   0.060   − 0.110   0.916^ns^

Performance data (ACC and RT) is presented for go and no-go trial data from go/no-go blocks. Oxy-Hb values for right CH10 are presented as functional data. For ADHD subjects, data for 1st day pre-medication, post-medication of placebo and MPH are shown. *t*-value, *p*-value and statistical significance were the results of *t*-tests between control and each ADHD condition. Abbreviations: SD, standard deviation; *t*, *t*-value; *p*, *p*-value. Statistical significances are presented as follows: ^⁎^, *p* \< 0.05; ^⁎⁎^, *p* \< 0.01; and ns, not significant.

###### 

ADHD inter-medication (placebo vs. MPH) comparison.

                                  Mean    SD      *t*     *p*
  ------------------------------- ------- ------- ------- -----------
  ACC for go trials (%)           1.98    8.12    0.975   0.345^ns^
  ACC for no-go trials (%)        0.03    11.2    0.011   0.991^ns^
  RT for correct go trials (ms)   0.84    54.3    0.062   0.951^ns^
  Oxy-Hb right CH10 (mM·mm)       0.084   0.088   3.809   0.002^⁎⁎^

Abbreviations: SD, standard deviation; *t*, *t*-value; *p*, *p*-value. Statistical significances are presented as follows: ^⁎^, *p* \< 0.05; ^⁎⁎^, *p* \< 0.01; and ns, not significant.

[^1]: These two authors contributed equally to this work.
